Literature DB >> 19487263

Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.

Anand N Malaviya1, Sanjiv Kapoor, Shriram Garg, Roopa Rawat, Subramanian Shankar, Savita Nagpal, Dinesh Khanna, Daniel E Furst.   

Abstract

OBJECTIVE: To test the efficacies of a strategy for preventing tuberculosis (TB) in Indian patients with inflammatory rheumatic diseases (IRD) treated with tumor necrosis factor-alpha (TNF-alpha) inhibitor.
METHODS: The screening strategy included tuberculosis skin test (TST), QuantiFERON-TB Gold (QTG) test, standard chest radiograph, and contrast enhanced-computerized tomography of the chest (CT).
RESULTS: Among 53 patients screened, 17 (32%) had >or= 1 test positive, with 5 (9.4%) patients having TB infection (clinical, CT, biopsy). The remaining 12 patients showed latent TB; 1 additional patient with negative screening tests was diagnosed with latent TB retrospectively for he developed TB disease within a few weeks of receiving infliximab. The remaining 35 patients tested negative with all tests. The combination of 4 screening tests gave a sensitivity of 0.83, specificity of 0.74, positive predictive value (PPV) 0.29, and negative predictive value (NPV) 0.97. Only 22 patients could afford treatment with TNF-alpha inhibitors; 19 of them were negative in the screening tests. Three patients who were positive on TST and/or QTG received prophylactic treatment with TNF-alpha inhibitor. Since implementation of the screening strategy, only 1 of 22 (4.5%) patients given TNF-alpha inhibitor developed probable TB disease.
CONCLUSION: With the use of these 4 TB screening tests in India, where TB is highly prevalent, TB could be excluded with a high degree of certainty (NPV 0.97). However, as even this combination of tests has only moderate sensitivity and specificity and poor PPV for detecting TB, vigilance may be advisable even if only one of the tests is positive.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19487263     DOI: 10.3899/jrheum.081042

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

1.  [Clinical presentation of tuberculosis in routine practice].

Authors:  R Dinser; M Frerix; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2012-10       Impact factor: 1.372

2.  Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents.

Authors:  Kyeong-Hee Kim; Sung-Won Lee; Won-Tae Chung; Byoung-Gwon Kim; Kwang-Sook Woo; Jin-Yeong Han; Jeong-Man Kim
Journal:  Korean J Lab Med       Date:  2011-10-03

3.  Positive tuberculin skin test or interferon-gamma release assay in patients with radiographic lesion suggesting old healed tuberculosis.

Authors:  Yun-Jeong Jeong; Soonho Yoon; Hyeon-kyoung Koo; Hyo-Jeong Lim; Ji Sun Lee; Sang-Min Lee; Seok-Chul Yang; Chul-Gyu Yoo; Young-Whan Kim; Sung-Koo Han; Jae-Joon Yim
Journal:  J Korean Med Sci       Date:  2012-06-29       Impact factor: 2.153

4.  Use of low-dose computed tomography to assess pulmonary tuberculosis among healthcare workers in a tuberculosis hospital.

Authors:  Wei He; Bu-Dong Chen; Yan Lv; Zhen Zhou; Jin-Ping Xu; Ping-Xin Lv; Xin-Hua Zhou; Feng-Gang Ning; Cheng-Hai Li; Dong-Po Wang; Jie Zheng
Journal:  Infect Dis Poverty       Date:  2017-03-24       Impact factor: 4.520

5.  Pleural Tuberculosis following Infliximab Therapy for Ankylosing Spondylitis.

Authors:  V S Gokul Krishnan; Sharath Madhyastha; Kusugodlu Ramamoorthi; Raviraj V Acharya; Vinaya Gopalaswamy
Journal:  J Pharmacol Pharmacother       Date:  2017 Jan-Mar

6.  Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-α therapy.

Authors:  In Kyung Yoo; Rok Seon Choung; Jong Jin Hyun; Seung Young Kim; Sung Woo Jung; Ja Seol Koo; Sang Woo Lee; Jai Hyun Choi; Ho Kim; Hong Sik Lee; Bora Keum; Eun Sun Kim; Yoon Tae Jeen
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

7.  Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia.

Authors:  Sandra V Navarra; Boxiong Tang; Liangjing Lu; Hsiao-Yi Lin; Chi Chiu Mok; Paijit Asavatanabodee; Parawee Suwannalai; Heselynn Hussein; Mahboob U Rahman
Journal:  Int J Rheum Dis       Date:  2013-10-16       Impact factor: 2.454

8.  Ulcerative intestinal tuberculosis case as a complication of treatment by infliximab for intestinal Behçet's disease: A case report.

Authors:  Yan Shen; Hai-Fen Ma; Yan-Li Yang; Jian-Long Guan
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.